文献速递细菌感染、耐药与抗菌药物

商业化AD磷霉素药敏试验对多重耐药肠杆菌目和铜绿假单胞菌的评价

Evaluation of the commercial AD fosfomycin test for susceptibility testing of multidrug-resistant Enterobacterales and Pseudomonas aeruginosa.
PubMed 文献 · Clin Microbiol Infect · 2020-12-05

本研究比较商业化琼脂稀释(AD)磷霉素试验与参考AD方法,检测119株产碳青霉烯酶肠杆菌目、53株产AmpC或ESBL肠杆菌目及38株产碳青霉烯酶铜绿假单胞菌。商业化试验总体一致性良好,肠杆菌目CA 91.9%、EA 92.5%,铜绿假单胞菌CA 100%(暂定折点128 mg/L)。

要点

  • 商业化AD磷霉素对MDR肠杆菌目与参考AD一致性良好。
  • 肠杆菌目主要错误率9.8%,无极重大错误。
  • 铜绿假单胞菌在暂定折点128 mg/L时CA达100%。

核心结论

  • 商业化AD磷霉素试验与参考AD方法总体一致性良好,可用于MDR肠杆菌目和铜绿假单胞菌的磷霉素药敏检测。

研究设计与样本

  • 研究纳入119株产碳青霉烯酶肠杆菌目、53株产获得性AmpC型或超广谱β-内酰胺酶肠杆菌目和38株产碳青霉烯酶铜绿假单胞菌临床分离株。
  • 商业化AD磷霉素试验与参考AD方法(ISO 20776-1:2019)从同一微生物悬液开始进行,结果按EUCAST临床折点(10.0)判读。

主要发现

  • 172株肠杆菌目中143株(83.1%)对磷霉素敏感,包括92.9%(52/56)的NDM生产者与84.2%(48/57)的KPC生产者。
  • 商业化AD磷霉素试验对肠杆菌目的CA为91.9%(158/172;95% CI 87.1%-95.3%),EA为92.5%(136/147;95% CI 87.4%-96.0%)。
  • 肠杆菌目主要错误率为9.8%(14/128),无极重大错误(0/29)。
  • 38株铜绿假单胞菌中86.8%(33/38)参考AD法MIC≤128 mg/L;商业化试验EA为84.8%(95% CI 66.3%-92.0%),暂定折点128 mg/L时CA为100%(95% CI 93.6%-100%)。

关键数值与推荐

  • 肠杆菌目:CA 91.9%(95% CI 87.1%-95.3%),EA 92.5%(95% CI 87.4%-96.0%),主要错误9.8%(14/128),极重大错误0%(0/29)。
  • 铜绿假单胞菌:暂定折点128 mg/L时CA 100%(95% CI 93.6%-100%),EA 84.8%(95% CI 66.3%-92.0%)。
  • 参考AD法敏感率:肠杆菌目83.1%(143/172),NDM生产者92.9%(52/56),KPC生产者84.2%(48/57)。

临床怎么用

  • 对于MDR肠杆菌目和铜绿假单胞菌,商业化AD磷霉素试验可作为参考AD法的替代用于磷霉素药敏检测。
  • 判读铜绿假单胞菌结果时需注意暂定折点128 mg/L下的CA,EA较低提示MIC值可能存在差异。

局限性

  • 铜绿假单胞菌的CA基于暂定折点128 mg/L计算,非正式临床折点。
  • 肠杆菌目EA计算仅纳入147株,并非全部172株。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare fosfomycin susceptibility testing with the commercial agar dilution (AD) test, AD Fosfomycin (Liofilchem, Roseto degli Abruzzi, Italy) and the reference AD method, using a collection of multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa clinical isolates. METHODS: The collection included 119 carbapenemase-producing Enterobacterales, 53 Enterobacterales producing acquired AmpC-type and/or extended-spectrum β-lactamases and 38 carbapenemase-producing P. aeruginosa, including representatives of different high-risk clones. AD Fosfomycin and AD reference method (ISO 20776-1:2019) were performed starting from the same microbial suspension. Results were interpreted according to EUCAST clinical breakpoints (10.0). Essential agreement (EA), category agreement (CA) and error rates were calculated as described by the International Organization for Standardization. RESULTS: Of 172 Enterobacterales, 143 (83.1%, including 92.9% (52 of 56) of the NDM-producers and 84.2% (48 of 57) of the KPC-producers) were susceptible to fosfomycin using reference AD. A CA of 91.9% (158 of 172; 95% CI 87.1%-95.3%) and an EA of 92.5% (136 of 147; 95% CI 87.4%-96.0%), respectively, were calculated for the commercial AD Fosfomycin test, with 9.8% (14 of 128) of major errors and no very major errors (0 of 29). Overall, 86.8% (33 of 38) of P. aeruginosa showed a fosfomycin MIC ≤128 mg/L using reference AD. An EA of 84.8% (95% CI 66.3%-92.0%) was calculated for the commercial AD Fosfomycin test, with a CA of 100% (95% CI 93.6%-100%) when considering a tentative breakpoint at 128 mg/L. CONCLUSIONS: AD Fosfomycin showed an overall good concordance compared with reference AD.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Parisio EM, Camarlinghi G, Coppi M, et al. Evaluation of the commercial AD fosfomycin test for susceptibility testing of multidrug-resistant Enterobacterales and Pseudomonas aeruginosa. Clin Microbiol Infect. 2020. PMID: 33285277. doi:10.1016/j.cmi.2020.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。